

Sister Study Self-Reported and Medically Confirmed Cancer Estimates by Primary Site of Origin, Excluding Non-Melanoma Skin Cancer

Table 1: Data Release 11.1^{1,2}

	Prevalent		Unknown Timing		Incident				
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		Total Incident
	N	N	N	%	N	%	N	%	N
Any Cancer (excluding NMSC)	2,848	258	1,902	22.7	374	4.5	6,118	72.9	8,394
Primary Site³									
Breast Cancer									
DCIS or invasive	61	13	758	16.4	59	1.3	3,811	82.3	4,628
LCIS	54	8	31	23.8	0	0.0	99	76.2	130
Reproductive Cancers									
Ovarian, fallopian tube, and peritoneal	207	16	71	22.9	43	13.9	196	63.2	310
Uterine (including endometrial)	377	38	102	22.3	23	5.0	332	72.6	457
Cervical	556	2	16	34.0	1	2.1	30	63.8	47
Vulvar	22	0	8	19.0	1	2.4	33	78.6	42
Vaginal	7	1	4	36.4	0	0.0	7	63.6	11
Endocrine Gland Cancers									
Thyroid	273	16	79	26.2	2	0.7	221	73.2	302

Abbreviations: DCIS = Ductal carcinoma *in situ*; LCIS = Lobular carcinoma *in situ*; NMSC = Non-melanoma skin cancer

¹ Data release 11.1 includes events from follow-up phases that closed on or before 9/30/2021, excluding all data from participants who have withdrawn their data from the study (n=5).

² See Table 2 for approximated estimates for additional cancer outcomes.

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#).

Table 2: Approximates Data Release 11.1^{1,2}

Primary Site ³	Prevalent	Unknown Timing	Incident						
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		Total Incident
	N	N	N	%	N	%	N	%	N
Digestive Cancers									
Colon and rectal (including appendiceal)	196	17	122	32.0	34	8.9	225	59.1	381
Small intestinal	0	1	4	28.6	5	35.7	5	35.7	14
Anal	4	1	9	23.1	1	2.6	29	74.4	39
Pancreatic	8	0	33	14.5	98	43.2	96	42.3	227
Biliary tract ⁴	1	1	11	34.4	8	25.0	13	40.6	32
Liver (including intrahepatic bile duct) ⁴	7	1	39	47.0	31	37.3	13	15.7	83
Stomach and esophageal	14	1	29	40.8	19	26.8	23	32.4	71
Lower Respiratory and Intrathoracic Cancers									
Bronchus and lung	64	9	164	24.6	198	29.7	304	45.6	666
Head and Neck Cancers									
Lip, oral cavity, pharynx, and upper respiratory tract	26	6	31	29.0	8	7.5	68	63.6	107
Urinary Cancers									
Kidney	59	2	48	27.0	12	6.7	118	66.3	178
Bladder	61	1	31	20.5	8	5.3	112	74.2	151
Renal pelvis, ureter, urethra	2	0	5	19.2	2	7.7	19	73.1	26
Skin Cancers									
Melanoma of the skin	748	80	393	36.3	5	0.5	686	63.3	1,084
Lymphoid and Hematopoietic Cancers									
Non-Hodgkin's lymphoma	89	6	74	23.0	21	6.5	227	70.5	322
Hodgkin's lymphoma	27	8	9	47.4	3	15.8	7	36.8	19
Multiple myeloma	6	1	20	17.4	12	10.4	83	72.2	115
Leukemia	55	10	74	28.1	32	12.2	157	59.7	263
Myelodysplastic syndrome	3	0	9	19.6	12	26.1	25	54.3	46
Polycythemia vera	3	2	12	52.2	1	4.3	10	43.5	23
Brain and Other Central Nervous System Cancers									
Brain tumors (malignant and benign)	67	21	169	39.9	48	11.3	207	48.8	424
Eye and adnexa	9	2	10	76.9	0	0.0	3	23.1	13
Other central nervous system	1	5	9	100.0	0	0.0	0	0.0	9

Other and Unspecified Cancers									
Bone	14	2	38	77.6	2	4.1	9	18.4	49
Mesothelium and soft tissue	20	6	14	23.3	14	23.3	32	53.3	60
Gastrointestinal stromal tumor	3	0	9	32.1	0	0.0	19	67.9	28
Neuroendocrine	20	4	19	19.6	0	0.0	78	80.4	97
Any other cancer, specified or unspecified (excluding NMSC)	80	487	141	43.7	48	14.9	134	41.5	323

Abbreviation: NMSC = Non-melanoma skin cancer

¹ Data release 11.1 includes events from follow-up phases that closed on or before 9/30/2021, excluding all data from participants who have withdrawn their data from the study (n=5).

² These baseline and self-reported estimates are likely an over-estimate of the actual number of cases.

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#).

⁴ Intrahepatic bile duct cancer diagnoses are only included in liver cancer counts. They are excluded in biliary tract cancer counts.